Pricing Log in Create free account
Friday 6 November 2026 Export PCVX’s income statement to Excel — free account

Vaxcyte, Inc.

PCVX Healthcare Biotechnology

EPS
−27.9%
Free cash flow
−92.6%

Quarter to September 2026, against a year earlier

63.82 1.90 +3.07%
Market cap
$9.8B
P/E
0.0×
Fwd P/E
—
Dividend yield
—
F-score
n/a
Altman Z
n/a
Beneish M
n/a
Dividend safety
n/a
Overview Business Profile Earnings & Analysis
Financials
Income Statement Balance Sheet Cash Flow Metrics & Ratios
Valuation Filings

Vaxcyte, Inc. 8-K filed Jun 23, 2026

Period ended Jun 17, 2026 · Filed · accepted 4:09 PM ET · Document on sec.gov · Filing index

5.02 Departure or appointment of directors or officers

Nothing in this filing raised a red flag, and we have no summary of it. The items it reports are listed above; the document itself is on sec.gov.

Read the filing on sec.gov